Barbara Depree, MD
Obstetrics & Gynecology · Zeeland, MINPI 1265417190
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Astellas Pharma US Inc at 50.0% of the total. Reporting peaked in 2019 at $44,777 and has fallen 65.0% since, to $15,670 in 2025. Among obstetrics & gynecology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $677.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$59K
- Duchesnay USA Incorporated$45K
- Astellas Pharma Global Development$14K
- Therapeuticsmd, Inc.$296
- AbbVie$246
- Myovant Sciences Inc.$43
- plus $232 from 11 others
Across 3 payments — averaging $2010.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$6K
What the payments were for
- Consulting fees$30,79126%
- Speaking & faculty fees$70,02059%
- Travel & lodging$13,16311%
- Food & beverage$4,4974%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 70 | $59,256 |
| Duchesnay USA Incorporated | 54 | $44,696 |
| Astellas Pharma Global Development | 13 | $13,713 |
| Therapeuticsmd, Inc. | 8 | $296 |
| AbbVie | 15 | $246 |
| Myovant Sciences Inc. | 2 | $43 |
| Pfizer | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Aspira Women's Health Inc | 1 | $30 |
| Millicent US Inc | 1 | $24 |
| Bayer | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Gilead | 1 | $16 |
| Ascend Therapeutics US, LLC | 1 | $16 |
| Amgen | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$118,483 in reported general payments places this provider in the 95th percentile of 1,474 obstetrics & gynecology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 169 | $28,483 |
| Estradiol (Twice Weekly)Estradiol | 167 | $27,866 |
| ProgesteroneProgesterone, Micronized | 179 | $10,346 |
| DottiEstradiol | 53 | $8,029 |
| OsphenaOspemifene | 13 | $6,393 |
| Estradiol (Once Weekly)Estradiol | 16 | $2,569 |
| YuvafemEstradiol | 11 | $2,140 |
| Triamcinolone Acetonide | 26 | $290 |
| Clobetasol Propionate | 20 | $249 |
| Medroxyprogesterone Acetate | 11 | $142 |
| Alendronate Sodium | 11 | $138 |
| Fluconazole | 18 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Duchesnay USA IncorporatedOsphena | $44,696 | $6,39313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,474 obstetrics & gynecology providers in Michigan.
Other obstetrics & gynecology in Zeeland
- David EisensteinDetroit$272K
- Peter TsengPort Huron$178K
- Robert ValiceChesterfield$175K
- Brent DavidsonDetroit$171K
- Michael EngelLake Orion$165K
- Ethan GoldsteinBloomfield Hills$140K
- Jay FisherWest Bloomfield$136K
- Rabbie HannaDetroit$105K
- Gregory GresselGrand Rapids$85K
- Ira FryeOwosso$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.